Looks like without the treatment with a stock promotion the shares of Neurokine Pharms Inc (OTC:NEUKF) would slowly sink into oblivion.
NEUKF has been marked with the sign of investor indifference during yesterday’s trading session, not being traded at all.
The number of only 300 shares changing hands on Wednesday was a signal that something goes wrong with the company or its stock.
The company’s official disclosures have no content that may slow down the trading of the shares at the present scale.
At the end of last year, Neurokine Pharms, Inc. made a change in its management body in an attempt to change the slow beat of its development, which reflects also on the performance of the shares.
Looks like up to now the results of these changes are not to be seen.
Further more, the demand for NEUKF stock became weaker. The company’s projects pipeline also remains almost at its stage of 2008. Then, the company filed in the USA its patent for the use of etanercept in post-CABG patients.
It is good that these days a stock promoter’s pipeline with an included project for NEUKF stock may bring shares explosive pulse again. It was like this last December.
At present, for the purpose of increasing public awareness in NEUKF, the stock promoter is compensated twenty five dollars cash. In the disclosure of the promotion, there is no information how long the shares of Neurokine Pharms, Inc. will be on the promoter’s artificial breathing.
Thanks to the above, today it is expected a more inspired and not so boring trading session of NEUKF.[BANNER]
Neurokine Pharms, Inc. is a development stage bio pharmaceutical company incorporated in June 2002 in Canada. Being still at a development stage and passing through several name changes, the company succeeded not to change its business approach as many others do it.
Neurokine Pharms, Inc. may be also a good example of a company with chaste financials, which seems were not able to be the decisive argument in favor of investors’ decision to invest in NEUKF.
To the contrary of the company’s financial reports with no long-term debts and accumulated deficit of 986K Canadian dollars, stock promotions already tested last year may be the correct medicine for the sinking NEUKF.
